Soros Fund Management’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Soros Fund Management’s Portfolio CERE Stock Details CERE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-2,151,641	Closed	-$88M	–	242
2024 Q2	$88M	Buy	2,151,641 +211,440	+11%	+$8.81M	1.58%	13
2024 Q1	$82M	Buy	+1,940,201	New	+$81.5M	1.36%	19

Other funds holding CERE

IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

Soros Fund Management's CERE Position: Q3 2024 in Review

Soros Fund Management sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 2,151,641 shares — an estimated $88M sold.

Soros Fund Management first reported a position in CERE in Q1 2024 and held it in 2 quarters. The position peaked at $88M in Q2 2024. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

Soros Fund Management reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
Soros Fund Management sold 2,151,641 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $88M.
Soros Fund Management first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q1 2024 and held it in 2 quarters.
Soros Fund Management's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $88M in Q2 2024.
2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on Soros Fund Management's 13F filing for Q3 2024, filed 14 Nov 2024.